Implications of Polymorphisms in the BCKDK and GATA‐4 Gene Regions on Stable Warfarin Dose in African Americans

• Main Authors: Salma A. Bargal, Jennifer N. Kight, Felipe Augusto de Oliveira, Mohamed H. Shahin, Taimour Langaee, Yan Gong, Issam S. Hamadeh, Rhonda M. Cooper-DeHoff, Larisa H. Cavallari
• Format: Article
• Language: English
• Published: Wiley 2021-03-01
• Series: Clinical and Translational Science
• Online Access: https://doi.org/10.1111/cts.12939
• ISSN: 1752-8054; 1752-8062

VKORC1 and CYP2C9 genotypes explain less variability in warfarin dose requirements in African Americans compared with Europeans. Variants in BCKDK and GATA‐4 gene regions, purported to regulate VKORC1 and CYP2C9 expression, have been shown to play an important role in warfarin dose requirements in Europeans and Asians, respectively. We sought to determine whether rs56314408 near BCKDK or GATA‐4 rs2645400 influence warfarin dose requirements in 200 African Americans. Unlike the strong linkage disequilibrium (LD) between rs56314408 and VKORC1 rs9923231 in Europeans, they were not in LD in African Americans. No associations were found on univariate analysis. On multivariable analysis, rs56314408 was associated (P = 0.027) with dose in a regression model excluding VKORC1 rs9923231, and GATA‐4 rs2645400 was associated (P = 0.032) with dose in a model excluding CYP2C (CYP2C9*2, *3, *5, *6, *8, and *11, CYP2C rs12777823) variants. Neither variant contributed to dose in the model that included both VKORC1 rs9923231 and CYP2C variants. Our results do not support contributions of the studied variants to warfarin dose requirements in African Americans. However, they illustrate the value of studies in African descent populations, who have low LD in their genome, in teasing out genetic variation underlying drug response associations. They also emphasize the importance of confirming associations in persons of African ancestry.